Literature DB >> 14582769

Symptomatic medication use in multiple sclerosis.

G Brichetto1, M Messmer Uccelli, G L Mancardi, C Solaro.   

Abstract

Multiple sclerosis (MS) is one of the most studied neurological diseases, although scarce attention has been placed on symptomatic therapy. The aim of the study was to evaluate the frequency of medication prescription for the major symptoms related to MS in order to better understand the needs of patients. The study was conducted during an epidemiological survey in the province of Genoa, Italy. Out of 856 patients with MS in the study area, 665 agreed to participate in a structured interview. Two hundred and forty-nine (37%) subjects, with a mean age of 53 years and a mean Expanded Disability Status Scale (EDSS) score of 5.2, were taking at least one symptomatic medication. Four hundred and sixteen (63%) subjects, with a mean age of 49 years and a mean EDSS score of 4.5, were not using symptomatic therapy. The most commonly treated symptoms were pain (28%), spasticity (27%) and mood disorder (16%), while bladder dysfunction (8%) and fatigue (3%) were less frequently treated with medication. Seventy-seven patients (12%) were taking medications for reasons not directly related to MS. This cross-sectional study underlines the frequency of medication prescription for symptoms such as spasticity and pain, while other common symptoms, such as bladder dysfunction and fatigue, may perhaps be undertreated. The present findings also underline the need for clinical trials on symptomatic therapies.

Entities:  

Mesh:

Year:  2003        PMID: 14582769     DOI: 10.1191/1352458503ms957oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  16 in total

1.  Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.

Authors:  Claudio Solaro; M Cella; Alessio Signori; Vittorio Martinelli; Marta Radaelli; D Centonze; F Sica; M G Grasso; A Clemenzi; S Bonavita; S Esposito; F Patti; E D'Amico; G Cruccu; A Truini
Journal:  J Neurol       Date:  2018-02-05       Impact factor: 4.849

2.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions.

Authors:  Joanie Thelen; Valeriy Zvonarev; Sarah Lam; Crystal Burkhardt; Sharon Lynch; Jared Bruce
Journal:  Mo Med       Date:  2021 May-Jun

Review 3.  Pharmacological management of pain in patients with multiple sclerosis.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

Review 4.  Management of pain in multiple sclerosis: a pharmacological approach.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 5.  Role of cannabinoids in multiple sclerosis.

Authors:  John P Zajicek; Vicentiu I Apostu
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

Review 6.  Pain and multiple sclerosis: pathophysiology and treatment.

Authors:  Claudio Solaro; Erika Trabucco; Michele Messmer Uccelli
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

7.  The symptomatic management of multiple sclerosis.

Authors:  Randall T Schapiro
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

8.  Predictors of Fatigue Impact in Persons With Long-Standing Multiple Sclerosis.

Authors:  Janet D Morrison; Alexa K Stuifbergen
Journal:  J Neurosci Nurs       Date:  2016-06       Impact factor: 1.230

Review 9.  A systematic review of pharmacological pain management in multiple sclerosis.

Authors:  Rachel Jawahar; Unsong Oh; Shibing Yang; Kate L Lapane
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

10.  Willingness to pay for a treatment for pain in multiple sclerosis.

Authors:  Michael Iskedjian; Olivier Desjardins; Charles Piwko; Basil Bereza; Barbara Jaszewski; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.